Management of Xylazine-Induced Soft-Tissue Necrosis: A Review of 20 Cases.
Helene RetrouveyMaximilian A MeyerKyros IpaktchiAndrew MaertensMatthew FolchertAlexander LauderPublished in: The Journal of the American Academy of Orthopaedic Surgeons (2024)
Acute treatment of xylazine-related soft-tissue necrosis is ideal to minimize morbidity and prevent limb loss. Management strategies of these wounds should be based on the depth of tissue involvement. Superficial ulceration involving the skin and subcutaneous tissue (Stage 1) should be managed with local wound care. Deeper ulceration involving tendons and/or muscle (Stage 2) requires surgical débridement and soft-tissue reconstruction. Deeper ulceration involving bone (Stage 3) requires osseous débridement and reconstruction. Finally, when all tissues in the extremity are involved (Stage 4), amputation is often necessary.